Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Feline leukemia virus envelope antigen p45
Virbac S.A.
QI06AA01
Feline leukemia virus envelope antigen p45
.
Suspension for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Cats
feline leukaemia virus
Immunological - Inactivated Vaccine
Authorised
2007-09-21
Health Products Regulatory Authority 18 July 2017 CRN000VVS Page 1 of 4 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Leucogen 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (1.0 ml) contains: ACTIVE SUBSTANCE: FeLV recombinant p45 antigen Minimum: 97 micrograms Target 102 micrograms ADJUVANT: Aluminium hydroxide gel (3%) 0.1 ml Quil A 10 micrograms EXCIPIENTS: For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of healthy cats to prevent persistent feline leukaemia-virus viraemia and any associated clinical signs of feline leucocis. The onset of protection begins 2 weeks after immunisation and the duration of protection lasts one year after the basic vaccination. Health Products Regulatory Authority 18 July 2017 CRN000VVS Page 2 of 4 4.3 CONTRAINDICATIONS Refer to Section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS The vaccine should be administered in accordance with the usual aseptic conditions for vaccination. Vaccinate only healthy animals. It is recommended that animals be treated for intestinal parasites at least 10 days prior to vaccination. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS In the case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) Transient and small thickening or nodule, approximately 5-10 mm in size, may be observed at the injection site and disappear within 2 to 6 weeks without treatment. Occasionally, systemic reactions (hyperthermia, anorexia, lethargy) may occur within one or two days after vaccine administration. 4.7 USE DURING PREGNANCY, LACTATION OR LAY In the absence of supporting data, the vaccine should not be used in pregnant or lactating cats. 4.8 Read the complete document